Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PR
PRTC.LSE
PR
PRTC.LSE
PRTC.LSE
News
·
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
This article first appeared on GuruFocus. Release Date: September 22, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PureTech Health PLC ended H1 2026 with $220 million in cash and short-term investments, …
finance.yahoo.com · Sep 22, 2026
PureTech Health H1 Earnings Call Highlights
Key Points Interested in PureTech Health PLC Sponsored ADR? Here are five stocks we like better. PureTech reported $220 million in cash and short-term investments at the parent-company level and expects its operational runway to last through at least the end of 2028, excluding po…
finance.yahoo.com · Sep 22, 2026
Vor, with new CEO, changes course to target autoimmune disease
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Vor Biopharma is licensing rights to an immune disease drug from Chinese biotechnology company RemeGen, it said Wednesday,…
finance.yahoo.com · Jun 26, 2025
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, January 03, 2024--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and C…
finance.yahoo.com · Jan 3, 2024
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis…
finance.yahoo.com · Dec 22, 2023
PureTech Year End Update and Outlook for 2024
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position with estimated Consolidated Cash, Cash Equivalents and Short-Ter…
finance.yahoo.com · Dec 20, 2023
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
LYT-200 demonstrates favorable safety profile and anti-tumor activity in combination with anti-PD-1 agent, tislelizumab Three out of four patients treated so far with head and neck cancers experienced disease control, with one complete response and one partial response observed i…
finance.yahoo.com · Dec 7, 2023
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is supported by positive data from the EMERGENT clinical trial program s…
finance.yahoo.com · Nov 29, 2023
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, the primary endpoint in the trial…
finance.yahoo.com · Nov 17, 2023
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Orally administered LYT-300 achieved a statistically significant (p=0.0001) reduction in the stress hormone response, as measured by salivary cortisol, compared to placebo This proof-of-concept trial demonstrating a reduction in the physiological stress response supports the furt…
finance.yahoo.com · Nov 14, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PR
PRTC.LSE
PRTC.LSE
Buy
Sell
Market
Limit
Soon
PRTC.LSE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PRTC.LSE yet.
Related Tickers
Earnings